Soroush M, Abbaszadeh M, Soroosh S. The Study of Bone Density in Type 2 Diabetic Patients and Comparison with Non-Diabetic Patients Referred to Two Hospitals in Tehran , Iran. Biomed Pharmacol J 2014;7(2)
Manuscript received on :
Manuscript accepted on :
Published online on: 26-12-2015
How to Cite    |   Publication History
Views Views: (Visited 127 times, 1 visits today)   Downloads PDF Downloads: 465

Mohsen Soroush , Mohsen Abbaszadeh and Soosan Soroosh

Department of Internal Medicine, AJA University of Medical Sciences, Tehran, Iran.

DOI : https://dx.doi.org/10.13005/bpj/528

Abstract

At present, the prevalence of diabetes type 1 and 2 has been increasing; on the other hand, osteoporosis is the most common metabolic bone disease in the world. The dominant view is the increased risk of osteoporosis caused by diabetes type 1. At present, scientists are seeking answers to questions about the relationship between diabetes type 2 and osteoporosis. The aim of this study is to assess the relationship between these two diseases together. If yes, researches should be done as integrated to cure the disease. This study is a case-control one. Our study population was postmenopausal women referred to densitometry sector in Imam Reza and Milad Hospitals.

Keywords

Diabetes; Osteoporosis; Bone densitometry

Download this article as: 
Copy the following to cite this article:

Soroush M, Abbaszadeh M, Soroosh S. The Study of Bone Density in Type 2 Diabetic Patients and Comparison with Non-Diabetic Patients Referred to Two Hospitals in Tehran , Iran. Biomed Pharmacol J 2014;7(2)

Copy the following to cite this URL:

Soroush M, Abbaszadeh M, Soroosh S. The Study of Bone Density in Type 2 Diabetic Patients and Comparison with Non-Diabetic Patients Referred to Two Hospitals in Tehran , Iran. Biomed Pharmacol J 2014;7(2). Available from: http://biomedpharmajournal.org/?p=3206

Introduction

Diabetes is a metabolic disorder of metabolism in the body. In this disease, the body loses the ability to produce insulin or the body becomes resistant to the effects of insulin. Thus, the produced insulin cannot do its normal function.  Insulin lowers blood sugar levels by several mechanisms. There are two forms of diabetes. In diabetes type 1, the destruction of beta cells in the pancreas leads to defects in insulin production and in diabetes type 2, there is a progressive resistance to insulin in the body that ultimately may lead to the destruction of pancreatic beta cells and complete defects in insulin production.   It is characterized   in diabetes type 2 that genetic factors, obesity and lack of physical activity have an important role in its development[1]. There are two ways: Diabetes type 1, once known as juvenile diabetes or insulin-dependent diabetes before, is a chronic disease that occurs when pancreas (pancreatitis) secretes a small amount of insulin (A hormone needed to enter sugar into cells to produce energy) or does not secrete insulin at all. Several factors, including genetic factors and infection with certain viruses may cause diabetes type. Although diabetes type 1 usually occurs in childhood and adolescence, adults are also susceptible to this disease [2-3]. Diabetes type 2 (adultonset or noninsulin-dependent diabetes), is one of the most common types of diabetes and constitutes approximately 90% of patients with diabetes.   Unlike diabetes type 1, the body doesn’t produces insulin in diabetes type 2; but either the amount of insulin produced by the pancreas is not sufficient or body cannot use the produced insulin [4-5]. When there is no enough insulin in the body or the body does not use insulin, glucose (sugar) existing in the body cannot enter the body’s cells and causes an accumulation of glucose in the body and results in problem and insufficiency. Unfortunately, there is no complete cure for this disease, but it can be improved with a healthy diet, exercise and fitness. If diet and exercise are not enough, you need to initiate medication or insulin therapy[6-7] . Osteoporosis is another very common disease in which the density of bone is reduced and then, bone strength  decreases and bone becomes fragile that results in greater risk of fractures [8].Osteoporosis usually progresses slowly and no symptoms occur until a fracture occurs.  Osteoporosis can occur in any bone in the body, but it is more often in spine, pelvic, wrist and ribs. Bone is a living tissue and has blood vessels and living cells. It is being alive that lets it grow and self-repair. Over a lifetime, body bone is absorbed regularly by feeder cells in which it is (called osteoclasts) and at the same time, it is replaced with new bone by osteoblast cells. Thus, all the bones in the body are constantly being new [9-10]. Building is more than absorbing in early childhood and adolescence, but it is contrariwise at older ages. Of course, body builds new bone even in the most severe cases of osteoporosis; just it is in small amounts.  The highest bone density is at about the age of twenty. Hormone levels have an impact on the continuous absorption and production of bone. The most important hormones influential in this process are the female hormone of estrogen and the male hormone testosterone and parathyroid hormone. Among these, estrogen has the greatest impact.  Genetic backgrounds and individual differences affect both in bone absorption and production and in its final result, namely, the strength and density of bone [11-13]. Most bones in the body are formed of a main body that is perforated and porous like a sponge and it is called cancellous bone on which a rigid layer of bone is covered with no holes and no porosity, called cortical bone.  In cortical area, bone is very dense and layered. In some parts of body, cancellous bone is more and in some parts cortical area.  Lattice and three-dimensional structure of bones is formed due to being light, while being strong too [14-15]. Cancellous bone porosity increases in osteoporosis, so that its pores become larger and the space between the rods of scaffold increases and rods of scaffold become thinner. Also cortical part on the bone becomes thinner. The relationship between the two diseases can be very important. In a study conducted by scientists, the results indicate the decrease in BMD at the lumbar spine and normal hip BMD in type 1 diabetic patients.  In another study performed on patients in Spanish, the results show a decrease in bone density at all sites in diabetic patients and in another study, no association between diabetes and bone density was emphasized.   In some cases, bone density at the femoral neck was higher even in diabetic patients [16-17] .

The aim of this study is to assess the relationship between diabetes, which is a very common today, and osteoporosis. On the one hand, osteoporosis is one of the most common diseases throughout the world. In case of being any relationship between these two diseases, researches should be focused as an integrated of cross-examination of both diseases to cure.

Material and Methods

This study is a case-control one. Our study population was 148 postmenopausal women referred to Imam Reza and Milad Hospitals in 2011. At first, the survey questionnaire, including check list of demographic information and questions relevant to main variables, was designed and after completion by the researcher from two  densitometry centers in Imam Reza hospital (501) and Milad hospital and recording bone density by Norland device, data were extracted and recorded. Then, subjects were divided into two diabetic and non-diabetic groups and patients were examined in terms of confounding variables include male gender, smoking, history of surgery, hyperthyroidism and non-menopausal women and were excluded, if they had above items. Data collected from the patients were entered into SPSS software. In the study of quantitative variables, the distribution of variables was studied using Kolmogorov – Smirnov (KS) and P Value> 0.05 was regarded as a normal distribution. According to their distribution, parametric and non-parametric tests were used to compare the mean of each group.   Descriptive data was expressed as mean, median and percentage.

Results

Demographicandunderlyinginformation: Inthisstudy,a total of148subjectswere studied, of these,69patientswerediabetic and79non-diabetic. The meanage ofdiabetic and non-diabetic patientsparticipating in thestudy was59 and 57 years old, respectively. BMI indiabeticand non-diabetic was98 and 28.36, respectively.  Based on theparametrictest   of independent-samples t-test, both groupswerematchedin terms ofBMI. The average age ofmenopauseindiabeticand non-diabetic groups was 47.83 and 48.06, respectively, which indicatesthat both werematchedon thisvariable. Family history ofdiabeteswas studiedintwo groups. According to the results, 37.3% of diabeticand 35.9% of non-diabetic patientshad a family historyofdiabetes.  Chi-squaretest resultsindicatedconsistencybetween the two groupson thisvariable.  17.4% of diabetics and17.8% of non-diabetic patientshas a history ofbone fractures.   Calciumintakewasalsosimilarin bothstudied groups. The averageduration ofdiabetes was 7 years in diabetic group, varying between 1 to20years.

The resultsof qualitative study of bonedensitometry variable

A statistically significant difference can be seen using chi-square test in both diabetic and non-diabetic groups for femoral BMD.

Table 1: Evaluation of femoral BMD in two groups (quantitatively)

Total Femoral BMD  
Osteoporosis Osteopenia Normal
69

100%

14

20.3%

30

43.5%

25

36.2%

Positive Diabetes
79

100%

26

32.9%

42

53.2%

11

13.9%

Negative

 

No statistically significant difference can be seen using chi-square test in both diabetic and non-diabetic groups for spine BMD.

Table 2: Evaluation of lumbar spine BMD in entire population (quantitatively)

Total Lumbar Spine BMD
Osteoporosis Osteopenia Normal
69

100%

7

10.1%

39

56.5%

23

33.3%

Positive Diabetes
79

100%

27

34.2%

48

60.8%

27

5.1%

Negative

The results of quantitative study of bonedensitometry variable

Kolmograph Smirnov test was used to assess this variable, with P <0.05. Distribution of variable in the study population is reported to be normal. About femur; using parametric test of independent-samples t-test P <0.05, so there was significant differences in terms of densitometry in two groups.

Table 3: Evaluation of femoral BMD in diabetic group (quantitatively)

Variable Number Mean SD Standard error of the mean Min. Max.
Femoral BM in diabetic group 69 0.79 0.13 0.016 0.52 1.18

Table 4: Evaluation of femoral BMD in control group (quantitatively)

Variable Number Mean SD Standard error of the mean Min. Max.
Femoral BM in diabetic group 79 0.74 0.10 0.012 0.49 1.14

 

About spine densitometry, the results of parametric test of independent-samples t-test showed that there is no significant relationship between diabetes and spine density (p> 0.05).

Discussion

In our study, two diabetic and non-diabetic groups were similar in terms of age, jobs, BMI, menopause age, menarche age, family history of osteoporosis, history of fractures in themselves or first-degree family, calcium intake, history of chronic disease involved in osteoporosis and use of drugs involved in osteoporosis.   In addition, smokers and people with the history of gastric surgery and hyperthyroid were exclude in the study group due to the small numbers. we concluded that lumbar spine bone density was not significant in both groups. The result was the same in the study of the effect of diabetes type 2 on osteoporosis [18] and in the study of femoral neck and lumbar spine bone density [19].   In the study of bone turnover in postmenopausal women with diabetes type 2 using biochemical markers and assessment of bone mineral density (Turkey Study), density was higher at this location. In the study of bone mineral density in type 2 diabetic patients in Sanandaj, the bone density was lower at this location, but the difference of femoral neck bone density was significant in this study.   In this case, the density was higher in diabetics. There was no significant relationship in the study of the effect of diabetes type 2 on osteoporosis[18]and in the study of femoral neck and lumbar spine bone density [19].

Conclusion

based on results from our study it seems that diabetes type 2 not only doesn’t cause osteoporosis, but also has a protective effect.  The results of our research can be caused by the effects of antidiabetic drugs. Therefore it is recommended that a more comprehensive study to be done to investigate the effects of antidiabetic drugs on bone density.

References

  1. Janghorbani, M, Van Dam, R M, Willett, W C and Hu, F B. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. American journal of epidemiology 2007; 166: 495-505
  2. Trial, C. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England journal of medicine 2005; 353: 2643.
  3. Karvonen, M, Tuomilehto, J, Libman, I and LaPorte, R. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 883-892
  4. Nouwen, A, Winkley, K, Twisk, J, Lloyd, C, Peyrot, M, Ismail, K, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 2010; 53: 2480-2486
  5. Group, U P D S. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ: British Medical Journal 1998; 317: 703
  6. Amori, R E, Lau, J and Pittas, A G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Jama 2007; 298: 194-206
  7. Setter, S M, Iltz, J L, Thams, J and Campbell, R K. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clinical therapeutics 2003; 25: 2991-3026
  8. Homik, J, Suarez-Almazor, M E, Shea, B, Cranney, A, Wells, G and Tugwell, P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 1998; 2:
  9. Kanis, J A, Melton, L J, Christiansen, C, Johnston, C C and Khaltaev, N. The diagnosis of osteoporosis. Journal of Bone and Mineral Research 1994; 9: 1137-1141
  10. Cummings, S R, Kelsey, J L, Nevitt, M C and O’DOWD, K J. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiologic reviews 1985; 7: 178-208
  11. Fink, H A, Ewing, S K, Ensrud, K E, Barrett-Connor, E, Taylor, B C, Cauley, J A, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. The Journal of Clinical Endocrinology & Metabolism 2006; 91: 3908-3915
  12. Lufkin, E G, Wahner, H W, O’Fallon, W M, Hodgson, S F, Kotowicz, M A, Lane, A W, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Annals of Internal Medicine 1992; 117: 1-9
  13. Neer, R M, Arnaud, C D, Zanchetta, J R, Prince, R, Gaich, G A, Reginster, J-Y, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England journal of medicine 2001; 344: 1434-1441
  14. Horsman, A, Nordin, B, Aaron, J and Marshall, D. Cortical and trabecular osteoporosis and their relation to fractures in the elderly. Osteoporosis: recent advances in pathogenesis and treatment. University Park Press, Baltimore 1981; 175-185
  15. Hodsman, A B, Bauer, D C, Dempster, D W, Dian, L, Hanley, D A, Harris, S T, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine reviews 2005; 26: 688-703
  16. Miazgowski, T, Pynka, S, Noworyta-Ziętara, M, Krzyzanowska-Świniarska, B and Pikul, R. Bone mineral density and hip structural analysis in type 1 diabetic men. European journal of endocrinology 2007; 156: 123-127
  17. Munoz-Torres, M, Jodar, E, Escobar-Jimenez, F, Lopez-Ibarra, P and Luna, J. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcified tissue international 1996; 58: 316-319
  18. Sharifi, F, Ahmadi Moghaddam, N and Mousavi-Nasab, N. The effects of type ii diabetes on bone density in menopause women. Iranian Journal of Diabetes and Metabolism 2005; 5: 135-142
  19. Hossein-Nezhad, A, Larijani, B, Pajouhi, M, Adibi, H and Maghbouli, J. Type 2 diabetes mellitus and the effects of lifestyle on bone mineral density in pre-and postmenopausal women. Iranian Journal of Diabetes and Metabolism 2004; 3: 13-23
Share Button
(Visited 127 times, 1 visits today)

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.